An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Apararenone (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 26 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Feb 2016 New trial record